BioPlus Co Ltd
KOSDAQ:099430
BioPlus Co Ltd
Operating Expenses
BioPlus Co Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
Operating Expenses
-₩19B
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Suheung Co Ltd
KRX:008490
|
Operating Expenses
-₩74.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-10%
|
|
|
SD Biosensor Inc
KRX:137310
|
Operating Expenses
-₩393.4B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-83%
|
CAGR 10-Years
N/A
|
|
|
H
|
HLB Inc
KOSDAQ:028300
|
Operating Expenses
-₩120.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-30%
|
|
|
T
|
T&L Co Ltd
KOSDAQ:340570
|
Operating Expenses
-₩18.4B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
I
|
Interojo Co Ltd
KOSDAQ:119610
|
Operating Expenses
-₩24B
|
CAGR 3-Years
8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-4%
|
|
BioPlus Co Ltd
Glance View
BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.
See Also
What is BioPlus Co Ltd's Operating Expenses?
Operating Expenses
-19B
KRW
Based on the financial report for Dec 31, 2024, BioPlus Co Ltd's Operating Expenses amounts to -19B KRW.
What is BioPlus Co Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-34%
Over the last year, the Operating Expenses growth was -64%. The average annual Operating Expenses growth rates for BioPlus Co Ltd have been -52% over the past three years , -34% over the past five years .
